Featured Research

from universities, journals, and other organizations

Toward Genetically Guided Cancer Treatment: Gene Expression Test Reveals Critical Characteristics Of Breast Tumors

Date:
March 1, 2007
Source:
University of Texas M. D. Anderson Cancer Center
Summary:
Two critical characteristics of breast cancer that are important to treatment can be identified by measuring gene expression in the tumor, a research team led by scientists at the University of Texas M. D. Anderson Cancer Center reports in Lancet Oncology online.

Two critical characteristics of breast cancer that are important to treatment can be identified by measuring gene expression in the tumor, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in Lancet Oncology online.

Researchers developed and validated a new genomic microarray test that identifies whether a tumor's growth is fueled by the female hormone estrogen and the role of a growth factor receptor known as HER-2 that makes a tumor vulnerable to a specific drug. The status of these factors is now determined by pathology tests.

"This is one important step towards personalized diagnosis and treatment planning based on an integrated genomic test of an individual tumor," said senior author W. Fraser Symmans, M.D., associate professor in the M. D. Anderson Department of Pathology. The Lancet Oncology paper results are the latest in an effort by the research team to develop a single test to quickly and efficiently determine the characteristics and vulnerabilities of a patient's breast cancer and ultimately to guide treatment.

About 70 percent of breast cancers are estrogen-receptor positive and another 15 to 25 percent are human epidermal growth factor receptor-2 (HER-2) positive. Each receptor status requires different types of treatment.

The gene expression tests were 90 percent accurate for both receptors, which makes them comparable to, if not better than, existing pathology tests.

"This moves us closer to developing an integrated single genomic test that could estimate the risk of cancer relapse after surgery, determine the ER and HER2 receptor status, and also gauge the sensitivity of the tumor to hormone therapy and chemotherapy," says Lajos Pusztai, M.D., Ph.D., associate professor in the M. D. Anderson Department of Breast Medical Oncology, and team leader with Symmans.

ER-positive tumors are treated with estrogen-suppressing drugs such as Tamoxifen. Tumors that are HER-2 positive are sensitive to Herceptin, an antibody-based drug that binds to the HER-2 receptors, blocking them from coupling with growth factors that fuel breast cancer.

Last fall, the group published a study showing that a genomic microarray test can also predict a patient's response to chemotherapy. They also presented a paper in December showing that another genomic index predicts how an ER-positive patient will respond to hormonal therapy.

A prospective clinical trial will soon open at M. D. Anderson to use these tests to recommend treatment for patients with newly diagnosed stage I-III breast cancer.

In the Lancet Oncology paper, they employed an Affymetrix microarray to gather estrogen receptor and HER-2 receptor gene expression data from 495 breast cancer samples from seven institutions. The samples included both fine needle aspiration biopsies and traditional biopsies.

The team used 195 fine-needle biopsy samples to set gene expression thresholds that predicted ER-positive status with 90 percent accuracy and HER-2-positive status with 93 percent accuracy. They then applied those thresholds to two more validation studies involving the remaining samples, which showed that the initial results were both reliable and reproducible.

The gene expression tests disagreed with traditional immunohistochemical lab analysis of the tumors by 8 percent for ER and 11 percent for HER-2. The researchers note this degree of discrepancy is usual when different diagnostic methods are applied to the same samples.

The study was funded by the National Cancer Institute, the Breast Cancer Research Foundation and the Goodwin Foundation.

Co-authors with Symmans and Pusztai are: first author Yun Gong, M.D., and Nour Sneige, M.D., of the M. D. Anderson Department of Pathology; Kai Yan, Keith Anderson, and Kenneth Hess, of the M. D. Anderson Department of Biostatistics; Feng Lin, M.D., Vicente Valero, M.D., Daniel Booser, M.D., Jaime Mejia, M.D., and Gabriel Hortobagyi, M.D., of the M. D. Anderson Department of Breast Medical Oncology; Christos Sotiriou, M.D., Ph.D., Institut Jules Bordet, Brussels, Belgium; Fabrice Andre, M.D., of Institut Gustave Roussy, Villejuif, France; Frankie Holmes, M.D., John Pippen Jr., M.D., and Svetislava Vukelja, M.D., of U.S. Oncology-Texas Oncology; Henry Gomez, M.D., of the Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; and Luis Barajas, M.D., Departmento de Ginecologia Oncologica, Instituto Mexicano del Seguro Social, Guadalajara, Mexico.


Story Source:

The above story is based on materials provided by University of Texas M. D. Anderson Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Texas M. D. Anderson Cancer Center. "Toward Genetically Guided Cancer Treatment: Gene Expression Test Reveals Critical Characteristics Of Breast Tumors." ScienceDaily. ScienceDaily, 1 March 2007. <www.sciencedaily.com/releases/2007/02/070214221109.htm>.
University of Texas M. D. Anderson Cancer Center. (2007, March 1). Toward Genetically Guided Cancer Treatment: Gene Expression Test Reveals Critical Characteristics Of Breast Tumors. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2007/02/070214221109.htm
University of Texas M. D. Anderson Cancer Center. "Toward Genetically Guided Cancer Treatment: Gene Expression Test Reveals Critical Characteristics Of Breast Tumors." ScienceDaily. www.sciencedaily.com/releases/2007/02/070214221109.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Despite Health Questions, E-Cigs Are Beneficial: Study

Despite Health Questions, E-Cigs Are Beneficial: Study

Newsy (July 31, 2014) Citing 81 previous studies, new research out of London suggests the benefits of smoking e-cigarettes instead of regular ones outweighs the risks. Video provided by Newsy
Powered by NewsLook.com
Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins